Success Metrics

Clinical Success Rate

50.0%

Based on 1 completed trials

Completion Rate

50%(1/2)

Active Trials

7(64%)

Results Posted

300%(3 trials)

Terminated

1(9%)

Phase Distribution

Ph phase_2

45%

Ph phase_1

27%

Ph phase_3

27%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution11 total trials

Phase 1Safety & dosage

3(27.3%)

Phase 2Efficacy & side effects

5(45.5%)

Phase 3Large-scale testing

3(27.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(7)

Completed(1)

Terminated(2)

Other(1)

Detailed Status

Active, not recruiting4

Recruiting3

Withdrawn1

unknown1

Terminated1

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

50.0%

Most Advanced

Phase 3

Trials by Phase

Phase 13 (27.3%)

Phase 25 (45.5%)

Phase 33 (27.3%)

Trials by Status

withdrawn19%

unknown19%

active_not_recruiting436%

terminated19%

recruiting327%

completed19%

Recent Activity

7 active trials

Showing 5 of 11

active_not_recruitingphase_2

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)

NCT03775486

recruitingphase_1

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

NCT04665206

recruitingphase_2

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

NCT05061550

active_not_recruitingphase_3

A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

NCT05668988

active_not_recruitingphase_2

Osimertinib Plus Chemotherapy vs Osimertinib in EGFRm NSCLC With Persistence Week-3 ctDNA EGFRm After 1L Osimertinib

NCT04769388

View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials

NCT03775486Phase 2

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)

Active Not Recruiting

NCT04665206Phase 1

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

Recruiting

NCT05061550Phase 2

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Recruiting

NCT05668988Phase 3

A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

Active Not Recruiting

NCT04769388Phase 2

Osimertinib Plus Chemotherapy vs Osimertinib in EGFRm NSCLC With Persistence Week-3 ctDNA EGFRm After 1L Osimertinib

Active Not Recruiting

NCT04035486Phase 3

A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

Active Not Recruiting

NCT07004244Phase 1

Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies

Recruiting

NCT00754364Phase 2

Mono Versus Polichemotherapy in Non Small Cell Lung Cancer (NSCLC) Elderly Patients

Terminated

NCT04430933Phase 1

A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC

Withdrawn

NCT01639001Phase 3

A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients

Completed

NCT02737774Phase 2

Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation

Unknown

All 11 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 11